騰盛博藥-B：2023年度報告

Futu News16:38 · Announcements

Tengsheng Pharmaceutical-B (02137) granted a total of 5.752,500 share options and 821,500 restricted share units

Tengsheng Pharmaceutical-B (02137) issued an announcement. On March 28, 2024, the company purchased shares in accordance with 2023...

Zhitong FinanceMar 29 01:18

Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%

Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.

Futu NewsMar 28 10:44

Tengsheng Pharmaceutical-B (02137.HK) will actively seek external cooperation with R&D expenditure of 403 million yuan in 2023

Gelonghui, March 22 | Tengsheng Pharmaceutical-B (02137.HK) announced that for the year ended December 31, 2023, other revenue was RMB 163.7 million, an increase of RMB 55.8 million or 51.7% compared with RMB 107.9 million for the year ended December 31, 2022. This was mainly due to an increase in interest income of RMB 70.8 million due to rising interest rates on US dollar and Hong Kong dollar time deposits. This increase was partially offset by a reduction in revenue recognized by the Chinese government subsidy. For the year ended December 31, 2023, R&D expenditure was for the people

Gelonghui FinanceMar 22 19:07

BRII-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

Futu NewsMar 22 19:00 · Announcements

A major favorable raid, and the 1.6 trillion innovative drug sector is booming!

The advantage suddenly “smashed” into the pharmaceutical sector!

券商中國Mar 13 21:18